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NICE GuIdElINEs
Secondary prevention for patients after a myocardial 
infarction: summary of NICe guidance
J S Skinner,1 A Cooper,2 G S Feder,3 on behalf of the Guideline Development Group
This is one of a series of 
BMJ summaries of new niCe 
guidelines, which are based 
on the best available evidence; 
they will highlight important 
recommendations for clinical 
practice, especially where 
uncertainty or controversy exists.
Why read this summary?  
Although premature mortality from coronary heart 
disease in the United Kingdom has fallen since the 
1970s, it remains higher than in most other Western 
countries. After an acute myocardial infarction, 
many eligible patients are prescribed aspirin, β 
blockers, angiotensin converting enzyme inhibitors, 
and statins. Not everyone, however, is offered the 
most effective secondary prevention1 2—that is, all 
four of these drugs or other effective drugs—nor does 
everyone receive lifestyle advice and cardiac reha-
bilitation. This article summarises the most recent 
recommendations from the National Institute for 
Health and Clinical Excellence (NICE) on effective 
secondary prevention in patients after myocardial 
infarction.3 The detailed consideration of the evi-
dence is available in the full guideline (www.nice.
org.uk/CG048).
Recommendations
NICE recommendations are based on systematic 
reviews of best available evidence. For the guidance 
on secondary prevention for patients after a myocar-
dial infarction, in cases where minimal evidence was 
available, the guideline development group devel-
oped the recommendations on the basis of their own 
opinions and those of leading specialists; such rec-
ommendations are indicated with an asterisk (*). 
Every discharge summary after a myocardial inf-
arction should confirm this diagnosis and include 
results of investigations, future management plans, 
and advice on secondary prevention.*
lifestyle
Lifestyle advice should be consistent and take 
account of patients’ current habits; any changes 
should be tailored to the individual. 
Advise patients:
To take enough regular physical activity to increase 
exercise capacity (reduces total mortality), building 
this up to 20-30 minutes a day to the point of slight 
breathlessness
To quit smoking. Offer support, advice, and 
pharmacotherapy to those wishing to quit4 5
To eat a Mediterranean-style diet: more bread, 
fruit, vegetables, and fish; less meat; inclusion of 
products based on vegetable and plant oils rather 
than butter and cheese (reduces total mortality and 
the risk of myocardial infarction)
To consume at least 7 g of omega 3 fatty acids 
(from two to four portions of oily fish) a week. If 
•
•
•
•
within three months of the patient’s myocardial 
infarction they are not achieving this, consider 
offering at least 1 g daily of omega 3 acid ethyl 
esters treatment licensed for secondary prevention 
after myocardial infarction for up to four years. It 
is not recommended that omega 3 acid ethyl esters 
supplements  are routinely prescribed to  patients 
who have had a myocardial infarction  more than 
three months earlier (no evidence of benefit)
To keep weekly alcohol consumption within safe 
limits (no more than 21 units a week for men, 14 
units for women) and to avoid binge drinking 
(more than three drinks in 1-2 hours)*   
To achieve and maintain a healthy weight if 
overweight or obese. Offer appropriate advice and 
support.6
Advise patients against taking:
Supplements containing β carotene (may increase 
risk of cardiovascular death)
Vitamin E or C supplements (no evidence of 
benefit)
Folic acid supplements (no evidence of benefit).
Cardiac rehabilitation
All healthcare professionals (including senior medical 
staff) caring for patients after a myocardial infarction 
should actively promote cardiac rehabilitation.*
Offer cardiac rehabilitation with an exercise 
component to all patients (reduces total mortality), 
and provide access regardless of the patient’s 
age, sex, ethnicity, socioeconomic status, or 
comorbidities.
Include the following components in 
comprehensive cardiac rehabilitation: exercise 
(reduces total mortality), health education, and 
stress management (reduces anxiety, depression 
and the risk of non-fatal myocardial infarction). 
However, complex psychological interventions, 
such as cognitive behavioural therapy, should not 
be routinely offered.
Comprehensive cardiac rehabilitation may be 
offered as a validated home based programme 
(for example, the Edinburgh Heart Manual7) with 
follow-up by a trained facilitator.
Involve partners or carers, if the patient wishes.*
Include advice on return to work and to activities 
of daily living, taking into account the patient’s 
physical and psychological status, the nature 
of the activity or work proposed, and the work 
environment.*
Reassure patients that after recovery from a heart 
•
•
•
•
•
•
•
•
•
•
•
•
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attack, sexual activity presents no greater risk of 
triggering a subsequent attack than if the patient 
had never had one.
Take into account the patient’s wider health and 
social needs, which may involve economic needs, 
welfare rights, or  social support issues, especially 
for those in more deprived situations.*
Drug treatment after acute myocardial infarction
Treat all patients with the following combination: 
Angiotensin converting enzyme inhibitor 
(reduces mortality, the risk of myocardial 
infarction, and, in selected patients, the risk of 
developing heart failure) 
Aspirin (reduces cardiovascular mortality and 
morbidity) 
β blocker (reduces total mortality and 
cardiovascular morbidity) 
Statin (reduces total mortality and cardiovascular 
morbidity).
After a non-ST elevation myocardial infarction, 
treat patients with both clopidogrel and 
low dose aspirin for 12 months8 (reduces 
cardiovascular mortality and the risk of 
myocardial infarction and stroke). After an ST 
elevation myocardial infarction, treat patients 
for at least four weeks if this combination has 
been started within the first 24 hours (reduces 
total mortality and the risk of myocardial 
infarction and stroke). Thereafter, continue 
standard treatment, including low dose aspirin 
without clopidogrel, unless there are other 
indications to continue both.
In patients intolerant of both aspirin and 
clopidogrel, consider treatment with moderate 
intensity warfarin (aiming for an international 
normalised ratio of  2-3) instead (reduces  the risk 
of myocardial infarction). In patients intolerant of 
clopidogrel and who have a low risk of bleeding, 
consider treatment with aspirin and moderate 
intensity warfarin combined.
In patients already taking warfarin for another 
indication, continue warfarin; in those taking 
moderate intensity warfarin (international 
normalised ratio of 2-3) and who have a low risk 
of bleeding, consider adding aspirin.
Heart failure after myocardial infarction
Treat patients with heart failure and left 
ventricular systolic dysfunction with an 
aldosterone antagonist licensed for this 
indication, preferably after treatment with 
an angiotensin converting enzyme inhibitor, 
within three to 14 days of the acute myocardial 
infarction (reduces total mortality and the risk 
of hospital admission for cardiovascular events, 
including heart failure).
Cardiological assessment
Offer cardiological assessment, taking account 
of comorbidity, to all patients so that those who 
•
•
1�
2�
3�
4�
•
•
•
•
•
will benefit from coronary revascularisation 
for secondary prevention (reduces the risk of 
myocardial infarction and total mortality in 
appropriately selected patients) or from other 
cardiological interventions9 can be identified. 
overcoming barriers
Effective implementation of these recommenda-
tions depends on planning between specialist and 
generalist services. Thus, as secondary prevention 
measures are generally started before discharge, 
timely discharge summaries with recommendations 
for ongoing care are crucial.
Appropriate review and patient education in both 
primary and secondary care improves concordance 
with drug treatment. Some drugs will need further 
monitoring and doses increased for optimal efficacy. 
Standard models of care should include advice 
about lifestyle for all patients. Existing cardiac reha-
bilitation programmes should evaluate their current 
provision in relation to the recommendations and 
ensure continuity of care before and after discharge. 
The costing tool being developed by NICE can be 
used to estimate additional costs (www.nice.org.uk/
page.aspx?o=tools). 
As the NICE guidance includes recommendations 
for all patients who have had a previous myocardial 
infarction, general practitioners should review their 
disease registers and ensure that all eligible patients 
are being appropriately managed.
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